Nautilus gets funding to support migraine drug launch

New Jersey's Nautilus Neurosciences has received an undisclosed investment from Galen Partners to support commercialization of its migraine treatment Cambia, which is set to launch in the first half of this year. The company was founded in November 2009 and with the help of funding from Tailwind Capital. Nautilus also has a second drug candidate--PRO-571 for acute pain--in clinical trials.

"Over the past six months we have raised approximately $25 million," says James Fares, chairman and CEO Nautilus Neurosciences. "With the backing of Tailwind, Galen, and our management team, we are confident that Nautilus is poised to become a leading neurology-focused specialty pharmaceutical company."

- here's the release on Nautilus' round

Suggested Articles

Levo Therapeutics’ lead program did not beat placebo in a phase 3 study of Prader-Willi syndrome, a genetic disorder that causes insatiable hunger.

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.